<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="937">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01971957</url>
  </required_header>
  <id_info>
    <org_study_id>560-12</org_study_id>
    <nct_id>NCT01971957</nct_id>
  </id_info>
  <brief_title>Sjogren-Larsson Syndrome: Natural History, Clinical Variation and Evaluation of Biochemical Markers</brief_title>
  <acronym>SLS</acronym>
  <official_title>Sjogren-Larsson Syndrome: A Longitudinal Study of Natural History, Clinical Variation and Evaluation of Biochemical Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sjogren-Larsson syndrome (SLS) is a rare genetic disease in which patients typically exhibit
      ichthyosis (dry, scaly skin), intellectual disability, spasticity, seizures and a
      distinctive maculopathy. The purpose of this study is to define the clinical spectrum and
      natural history of Sjogren-Larsson syndrome, and identify biomarkers that correlate with
      disease phenotype while establishing a registry for future investigations of biochemical
      pathogenesis and therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of a clinical component and a scientific component consisting of
      laboratory investigations of potentially useful biochemical (lipid and protein) markers. Up
      to 50 SLS patients of all ages, gender and ethnic origins will be enrolled. A detailed
      clinical evaluation will be performed to determine the presence and extent of disease
      involving the skin, nervous system and eyes. Clinical testing will include brain magnetic
      resonance imaging (MRI) and spectroscopy (MRS), electroencephalography (EEG), neurocognitive
      tests, ophthalmologic examination with retinal photographs and optical coherence tomography
      (OCT), photographs of the skin and tests of cutaneous transepidermal water loss. Laboratory
      investigations will include lipid analyses (e.g. fatty alcohols, farnesol, fatty acids,
      ether glycerolipids, etc.) of blood, skin and urine; proteomic analysis of skin (stratum
      corneum); and measurements of leukocyte fatty alcohol and farnesol oxidation. A skin biopsy
      (optional) will be obtained for electron microscopy, measurement of lanthanum perfusion
      (transepidermal water loss), and/or establishing keratinocyte cultures. Correlations between
      clinical abnormalities and laboratory measurements will be tested to identify the most
      useful biomarkers for future diagnostic and therapeutic studies. To characterize the
      progression of phenotypic features over time, patients &lt;6 years of age will be followed
      yearly and patients ≥6 years of age will be followed every 3 years. In addition, a SLS
      patient registry will be established as a resource for future investigations in SLS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Characterize the extent and progression of neurocutaneous disease in patients with Sjogren-Larsson syndrome, and identify useful biomarkers.</measure>
    <time_frame>2017 (up to 5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Sjogren-Larsson Syndrome (SLS)</condition>
  <arm_group>
    <arm_group_label>Sjogren-Larsson syndrome</arm_group_label>
    <description>There are no cohorts for this study.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, urine, skin
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will come from cohorts of Sjögren-Larsson syndrome patients currently
        followed at STAIR sites, from the RDCRN contact registry, and from the pool of new
        patients who directly contact STAIR sites or are referred to STAIR centers by their
        physicians.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The only eligibility criterion is that subjects have a genetically or biochemically
             confirmed diagnosis of Sjogren-Larsson syndrome.

        Exclusion Criteria:

          -  The primary exclusion criteria are the patients' failure to consent or inability to
             travel to a STAIR site.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William B Rizzo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William B Rizzo, MD</last_name>
    <phone>4025592560</phone>
    <email>wrizzo@unmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachel Cooper, BS, AS</last_name>
    <phone>4022906738</phone>
    <email>rachel.cooper@unmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-5456</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William B Rizzo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Baptiste Roullet, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rizzo WB. Sjögren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency. Mol Genet Metab. 2007 Jan;90(1):1-9. Epub 2006 Sep 22. Review.</citation>
    <PMID>16996289</PMID>
  </reference>
  <reference>
    <citation>Lossos A, Khoury M, Rizzo WB, Gomori JM, Banin E, Zlotogorski A, Jaber S, Abramsky O, Argov Z, Rosenmann H. Phenotypic variability among adult siblings with Sjögren-Larsson syndrome. Arch Neurol. 2006 Feb;63(2):278-80.</citation>
    <PMID>16476818</PMID>
  </reference>
  <reference>
    <citation>Rizzo WB, Craft DA, Somer T, Carney G, Trafrova J, Simon M. Abnormal fatty alcohol metabolism in cultured keratinocytes from patients with Sjögren-Larsson syndrome. J Lipid Res. 2008 Feb;49(2):410-9. Epub 2007 Oct 30.</citation>
    <PMID>17971613</PMID>
  </reference>
  <reference>
    <citation>Fuijkschot J, Theelen T, Seyger MM, van der Graaf M, de Groot IJ, Wevers RA, Wanders RJ, Waterham HR, Willemsen MA. Sjögren-Larsson syndrome in clinical practice. J Inherit Metab Dis. 2012 Nov;35(6):955-62. doi: 10.1007/s10545-012-9518-6. Epub 2012 Jul 26. Review.</citation>
    <PMID>22833178</PMID>
  </reference>
  <reference>
    <citation>Rizzo WB. The role of fatty aldehyde dehydrogenase in epidermal structure and function. Dermatoendocrinol. 2011 Apr;3(2):91-9. doi: 10.4161/derm.3.2.14619. Epub 2011 Apr 1.</citation>
    <PMID>21695018</PMID>
  </reference>
  <reference>
    <citation>Rizzo WB, Carney G. Sjögren-Larsson syndrome: diversity of mutations and polymorphisms in the fatty aldehyde dehydrogenase gene (ALDH3A2). Hum Mutat. 2005 Jul;26(1):1-10. Review.</citation>
    <PMID>15931689</PMID>
  </reference>
  <reference>
    <citation>Willemsen MA, Van Der Graaf M, Van Der Knaap MS, Heerschap A, Van Domburg PH, Gabreëls FJ, Rotteveel JJ. MR imaging and proton MR spectroscopic studies in Sjögren-Larsson syndrome: characterization of the leukoencephalopathy. AJNR Am J Neuroradiol. 2004 Apr;25(4):649-57.</citation>
    <PMID>15090362</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 29, 2013</lastchanged_date>
  <firstreceived_date>April 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>William Rizzo, MD</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>ichthyosis</keyword>
  <keyword>spasticity</keyword>
  <keyword>spastic diplegia</keyword>
  <keyword>intellectual disability</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Sjogren-Larsson Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
